Literature DB >> 25012821

Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey.

I Faria-Ramos1, J Neves-Maia, E Ricardo, J Santos-Antunes, A T Silva, S Costa-de-Oliveira, E Cantón, A G Rodrigues, C Pina-Vaz.   

Abstract

This is the first Portuguese multicenter observational and descriptive study that provides insights on the species distribution and susceptibility profiles of yeast isolates from fungemia episodes. Ten district hospitals across Portugal contributed by collecting yeast isolates from blood cultures and answering questionnaires concerning patients' data during a 12-month period. Molecular identification of cryptic species of Candida parapsilosis and C. glabrata complex was performed. The susceptibility profile of each isolate, considering eight of the most often used antifungals, was determined. Both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) protocols were applied. The incidence of 240 episodes of fungemia was 0.88/1,000 admissions. Fifteen different species were found, with C. albicans (40 %) being the most prevalent, followed by C. parapsilosis (23 %) and C. glabrata (13 %). Most isolates were recovered from patients admitted to surgical wards or intensive care units, with 57 % being males and 32 % aged between 41 and 60 years. For both the CLSI and EUCAST protocols, the overall susceptibility rates ranged from 74 to 97 % for echinocandins and from 84 to 98 % for azoles. Important resistance rate discrepancies between protocols were observed in C. albicans and C. glabrata for echinocandins and in C. parapsilosis and C. tropicalis for azoles. Death associated with fungemia occurred in 25 % of the cases, with more than half of C. glabrata infections being fatal. The great number of Candida non-albicans is noteworthy despite a relatively low antifungal resistance rate. Studies like this are essential in order to improve empirical treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25012821     DOI: 10.1007/s10096-014-2194-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Epidemiology and management of candidaemia--a retrospective, multicentre study in five hospitals in the UK.

Authors:  C Chalmers; S Gaur; J Chew; T Wright; A Kumar; S Mathur; W Y Wan; I M Gould; A Leanord; A M Bal
Journal:  Mycoses       Date:  2011-05-25       Impact factor: 4.377

3.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Candidemia: incidence rates, type of species, and risk factors at a tertiary care academic hospital in China.

Authors:  Zengbin Wu; Yingbin Liu; Xiaobo Feng; Ying Liu; Shuyun Wang; Xiaodong Zhu; Qiqi Chen; Shuming Pan
Journal:  Int J Infect Dis       Date:  2014-02-28       Impact factor: 3.623

5.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

6.  Candidaemia in Sweden: a nationwide prospective observational survey.

Authors:  J Ericsson; E Chryssanthou; L Klingspor; A G Johansson; P Ljungman; E Svensson; J Sjölin
Journal:  Clin Microbiol Infect       Date:  2013-01-17       Impact factor: 8.067

7.  Distribution, virulence attributes and antifungal susceptibility patterns of Candida parapsilosis complex strains isolated from clinical samples.

Authors:  Ilknur Tosun; Zeynep Akyuz; Nejla Cebeci Guler; Dolunay Gulmez; Gulcin Bayramoglu; Nese Kaklikkaya; Sevtap Arikan-Akdagli; Faruk Aydin
Journal:  Med Mycol       Date:  2012-12-06       Impact factor: 4.076

8.  Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011.

Authors:  Lena Ros Asmundsdottir; Helga Erlendsdottir; Magnus Gottfredsson
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

9.  Looking for Candida nivariensis and C. bracarensis among a large Italian collection of C. glabrata isolates: results of the FIMUA working group.

Authors:  M C Esposto; A Prigitano; O Romeo; G Criseo; L Trovato; V Tullio; M E Fadda; A M Tortorano
Journal:  Mycoses       Date:  2012-11-21       Impact factor: 4.377

Review 10.  Epidemiology and risk factors for invasive candidiasis.

Authors:  Nur Yapar
Journal:  Ther Clin Risk Manag       Date:  2014-02-13       Impact factor: 2.423

View more
  19 in total

1.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

2.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Serious fungal infections in Portugal.

Authors:  R Sabino; C Verissímo; J Brandão; C Martins; D Alves; C Pais; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-10       Impact factor: 3.267

Review 5.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

6.  Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.

Authors:  Shawn R Lockhart; Cau D Pham; Randall J Kuykendall; Carol B Bolden; Angela A Cleveland
Journal:  Diagn Microbiol Infect Dis       Date:  2015-08-28       Impact factor: 2.803

7.  Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years?

Authors:  Judith Díaz-García; Aina Mesquida; Carlos Sánchez-Carrillo; Elena Reigadas; Patricia Muñoz; Pilar Escribano; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

8.  Genomic evolution towards azole resistance in Candida glabrata clinical isolates unveils the importance of CgHxt4/6/7 in azole accumulation.

Authors:  Mónica Galocha; Romeu Viana; Pedro Pais; Ana Silva-Dias; Mafalda Cavalheiro; Isabel M Miranda; Mieke Van Ende; Caio S Souza; Catarina Costa; Joana Branco; Cláudio M Soares; Patrick Van Dijck; Acácio G Rodrigues; Miguel C Teixeira
Journal:  Commun Biol       Date:  2022-10-21

9.  Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.

Authors:  Maria Teresa Montagna; Grazia Lovero; Caterina Coretti; Domenico Martinelli; Osvalda De Giglio; Roberta Iatta; Stella Balbino; Antonio Rosato; Giuseppina Caggiano
Journal:  BMC Microbiol       Date:  2015-05-20       Impact factor: 3.605

10.  Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance.

Authors:  Giuseppina Caggiano; Caterina Coretti; Nicola Bartolomeo; Grazia Lovero; Osvalda De Giglio; Maria Teresa Montagna
Journal:  Biomed Res Int       Date:  2015-05-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.